Diagnostic biomarkers of gut microbiome-associated phenotypes predictive of healthy ageing

肠道的不同细菌群与长寿和健康衰老有关，已经确定了引起免疫反应的特定细菌。该项目将定义微生物组和人类基因表达生物标记物的组合签名，以诊断健康老化的肠道表型以及相关的炎症性肠病(IBD)和/或神经退行性疾病。我们将应用最先进的微生物群测量方法和来自50-80岁患有和不患有炎症性肠病(IBD)和/或神经退行性疾病的肠道样本的基因表达谱。基因表达生物标记物将使用由南安普顿大学开发的TopMD AI增强技术来识别。通过应用数学拓扑学，TopMD创新性地使用已知的生物路径作为坐标来测量全球基因表达的“形状”，准确地将分子表型表示为一个强大的“路径生物标记物”。在这个项目中，我们正在与合作伙伴BioArte Ltd合作，将微生物组和基因表达签名的预测能力结合起来。BioArte有限公司正在通过识别从人类和动物微生物群中获得的分子来开发针对疾病的个性化药物。他们领导了免疫调节细菌和预测寿命的微生物组特征的发现。结合微生物组-宿主基因表达的健康老龄化生物标记物特征将发展成为50-80岁人群肠道微生物组相关性IBD和神经退行性疾病的首个此类诊断点测试。

Different bacterial populations of gut are associated with longevity and healthy ageing and specific bacteria have been identified which cause immune responses. This project will define combined microbiome and human gene expression biomarker signatures diagnostic of healthy ageing gut phenotypes and associated inflammatory bowel disease (IBD) and/or neurodegenerative disease.We will apply cutting edge measurement of microbiomes and gene expression profiles of gut samples from people aged 50 - 80 with and without inflammatory bowel disease (IBD) and/or neurodegenerative disease. Gene expression biomarkers will be identified using TopMD AI-enhanced technology, developed at the University of Southampton. By applying mathematical topology, TopMD innovatively uses known biological pathways as coordinates for measuring the 'shape' of global gene expression, accurately representing the molecular phenotype as a robust 'pathway biomarker'. In this project, we are working with partner The BioArte Ltd to combined predictive power of microbiome and gene expression signatures. The BioArte Ltd is developing personalised remedies for diseases by identifying molecules obtained from human and animal microbiota. They have led the discovery of immune-regulating bacteria and microbiome signatures predictive of longevity.The combined microbiome- host gene expression biomarker signatures of healthy ageing will be developed into a first of its kind diagnostic point of care test for gut microbiome-associated IBD and neurodegenerative disease in people aged 50-80\.